Reports: Roche raises DNA offer to $95 a share

Genentech's board may be ready to seal the deal after all. Although the company urged shareholders to sit tight after Roche uppeds its bid to $93 a share on Friday, the Wall Street Journal is reporting that the biotech and Roche were in discussions through the weekend. Sources close to the matter tell the WSJ that Roche has again raised its tender offer to $95 a share. A deal could be announced as soon as the close of the trading day.

The new offer values Genentech at $46.7 billion. DNA is currently up 2.4 percent, trading around $92.93.

- check out the WSJ report

Suggested Articles

The efficacy between Keytruda and FerGene's nadofaragene firadenovec look comparable in their studies, though Merck has at least one upper hand.

Thursday, the FDA approved the first three generic versions of Gilenya, but they may not hit the market anytime soon due to ongoing litigation.

Gilead is hoping to score a patent extension on TAF meds, but patient advocates say that would reward conduct that harmed patients.